RxDoctor Payments Data

Kimberly Burgess, MD

Urology · Greenville, SCNPI 1578760450

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (56.7%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Medtronic accounts for 93.1% of it on its own, with 11 other manufacturers making up the rest.

$10,690in general payments, 2019–2025

Across 77 payments — averaging $138.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$10K
  • Coloplast$376
  • Boston Scientific$126
  • Sumitomo Pharma America, Inc.$50
  • Endo USA, Inc.$36
  • Johnson & Johnson$31
  • plus $123 from 6 others
$263,527in research payments, 2019–2025

Across 66 payments — averaging $3992.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$264K

What the payments were for

  • Consulting fees$2,12520%
  • Travel & lodging$6,05957%
  • Food & beverage$2,50623%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,690 in reported general payments places this provider in the 80th percentile of 196 urology providers in South Carolina.

See all urology providers in South Carolina

Medicare billing

Part B allowed, 2024
$308,114
Medicare patients
547
Services billed
17,297

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron316$193,309
GemtesaVibegron214$157,519
Mirabegron ErMirabegron35$17,448
Estradiol93$4,762
Solifenacin Succinate155$4,288
Methenamine Hippurate38$2,664
Oxybutynin Chloride ErOxybutynin Chloride74$1,766
Trospium Chloride ErTrospium Chloride12$1,075
Oxybutynin Chloride17$789
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst42$500
NitrofurantoinNitrofurantoin Macrocrystal17$461
Cephalexin199$449
Tamsulosin Hcl32$272
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim71$118
Gentamicin Sulfate16$100

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$50$157,519214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 196 urology providers in South Carolina.

Other urology in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →